AU2001233132A1 - Hybrid adeno-retroviral vector for the transfection of cells - Google Patents
Hybrid adeno-retroviral vector for the transfection of cellsInfo
- Publication number
- AU2001233132A1 AU2001233132A1 AU2001233132A AU3313201A AU2001233132A1 AU 2001233132 A1 AU2001233132 A1 AU 2001233132A1 AU 2001233132 A AU2001233132 A AU 2001233132A AU 3313201 A AU3313201 A AU 3313201A AU 2001233132 A1 AU2001233132 A1 AU 2001233132A1
- Authority
- AU
- Australia
- Prior art keywords
- transfection
- cells
- retroviral vector
- hybrid adeno
- adeno
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17932700P | 2000-01-31 | 2000-01-31 | |
US60179327 | 2000-01-31 | ||
PCT/US2001/003026 WO2001055362A2 (en) | 2000-01-31 | 2001-01-30 | Hybrid adeno-retroviral vector for the transfection of cells |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001233132A1 true AU2001233132A1 (en) | 2001-08-07 |
Family
ID=22656101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001233132A Abandoned AU2001233132A1 (en) | 2000-01-31 | 2001-01-30 | Hybrid adeno-retroviral vector for the transfection of cells |
Country Status (3)
Country | Link |
---|---|
US (3) | US7052904B2 (en) |
AU (1) | AU2001233132A1 (en) |
WO (1) | WO2001055362A2 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002061104A2 (en) * | 2001-01-30 | 2002-08-08 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Hybrid adenoviral vector |
PL2486938T3 (en) | 2006-09-26 | 2018-08-31 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
ES2606563T3 (en) | 2009-06-05 | 2017-03-24 | Infectious Disease Research Institute | Synthetic glycopyranosyl lipid adjuvants and vaccine compositions containing the same |
US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
EP2694099B1 (en) | 2011-04-08 | 2019-10-16 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
US20140140962A1 (en) * | 2011-04-29 | 2014-05-22 | The Research Foundation Of State University Of New York | Viruses modified with unnatural moieties and methods of use thereof |
LT2811981T (en) | 2012-02-07 | 2019-06-10 | Infectious Disease Research Institute | Improved adjuvant formulations comprising tlr4 agonists and methods of using the same |
PL2850431T3 (en) | 2012-05-16 | 2018-09-28 | Immune Design Corp. | Vaccines for hsv-2 |
SG11201508092YA (en) | 2013-04-18 | 2015-10-29 | Immune Design Corp | Gla monotherapy for use in cancer treatment |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
WO2017200852A1 (en) | 2016-05-16 | 2017-11-23 | Infectious Disease Research Institute | Formulation containing tlr agonist and methods of use |
MX2018014399A (en) | 2016-06-01 | 2019-06-06 | Infectious Disease Res Inst | Nanoalum particles containing a sizing agent. |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
JP7339942B2 (en) | 2017-09-08 | 2023-09-06 | アクセス ツー アドバンスト ヘルス インスティチュート | Liposomal formulation containing saponin and method of use |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585362A (en) * | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
FR2716459B1 (en) * | 1994-02-22 | 1996-05-10 | Univ Paris Curie | Host-vector system usable in gene therapy. |
FR2723697B1 (en) * | 1994-08-17 | 1996-09-20 | Rhone Poulenc Rorer Sa | METHOD OF TREATING RESTENOSIS WITH GENE THERAPY |
DE69534166T2 (en) * | 1994-10-28 | 2006-03-09 | Trustees Of The University Of Pennsylvania | RECOMBINANT ADENOVIRUS AND METHODS OF USE THEREOF |
US5681746A (en) | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
US6156497A (en) * | 1996-01-05 | 2000-12-05 | Genetic Therapy, Inc. | Recombinase-mediated generation of adenoviral vectors |
AU728610B2 (en) * | 1996-11-19 | 2001-01-11 | University Of Alabama At Birmingham Research Foundation | Chimeric retrovirus/adenovirus system |
EP1042494A1 (en) | 1997-12-23 | 2000-10-11 | Introgene B.V. | Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells |
CA2327444A1 (en) * | 1998-04-29 | 1999-11-04 | Oklahoma Medical Research Foundation | Construction of retroviral producer cells from adenoviral and retroviral vectors |
GB9906615D0 (en) | 1999-03-22 | 1999-05-19 | Oxford Biomedica Ltd | Vector |
US20020150876A1 (en) | 2000-03-30 | 2002-10-17 | Pippig Susanne Dagmar | Selectable marker genes |
WO2002061104A2 (en) | 2001-01-30 | 2002-08-08 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Hybrid adenoviral vector |
-
2001
- 2001-01-30 AU AU2001233132A patent/AU2001233132A1/en not_active Abandoned
- 2001-01-30 WO PCT/US2001/003026 patent/WO2001055362A2/en active Application Filing
- 2001-01-30 US US10/182,644 patent/US7052904B2/en not_active Expired - Fee Related
-
2005
- 2005-10-19 US US11/255,059 patent/US7618623B2/en not_active Expired - Fee Related
-
2009
- 2009-06-19 US US12/488,464 patent/US20090258935A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20040115788A1 (en) | 2004-06-17 |
US7618623B2 (en) | 2009-11-17 |
WO2001055362A3 (en) | 2002-01-10 |
US7052904B2 (en) | 2006-05-30 |
US20090258935A1 (en) | 2009-10-15 |
WO2001055362A2 (en) | 2001-08-02 |
US20060035371A1 (en) | 2006-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001233132A1 (en) | Hybrid adeno-retroviral vector for the transfection of cells | |
AU3706700A (en) | Positively charged membrane | |
AU2002222112A1 (en) | Hybrid antibodies | |
AU2001240126A1 (en) | Lithium cell | |
AU2002351249A1 (en) | Battery charging system | |
EP1130098A3 (en) | Mammalian osteoregulins | |
AU2002241571A1 (en) | Multi-cell battery | |
AU3376400A (en) | Negatively charged membrane | |
AU5003600A (en) | Charged membrane | |
AU2926000A (en) | Packaging cells for retroviral vectors | |
AU5854100A (en) | Lithium cell | |
AU2003220161A1 (en) | Vector for transfection of eukaryotic cells | |
AU6974700A (en) | Rechargeable nickel-zinc cells | |
AU2002237701A1 (en) | Rapid battery charger | |
AU2001232054A1 (en) | Vector | |
AUPQ529000A0 (en) | Toner characterization cell | |
AU2001287064A1 (en) | Battery | |
AU2001267724A1 (en) | Electrochemical cell | |
AU2001257429A1 (en) | Battery | |
AU2001257430A1 (en) | Battery | |
AU5250100A (en) | Vector for expressing two foreign genes | |
AU2001269081A1 (en) | Electrochemical cells | |
AU4494300A (en) | Powertrain for power generator | |
AU7964400A (en) | Lithium secondary cell | |
AU1595401A (en) | Lithium primary batteries |